Naoya Kato

Dr. Naoya Kato

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
HMHidefumi Mukai
Hidefumi Mukai
KOKoki Ogawa
Koki Ogawa
NKNaoya Kato
Naoya Kato
SKShigeru Kawakami
Shigeru Kawakami

31 January 2023 in Drug Delivery
Verified
Journal Article
Open access
NKNaoya Kato
Naoya Kato
SYSakura Yamada
Sakura Yamada
RSRino Suzuki
Rino Suzuki
YIYoshiki Iida
Yoshiki Iida
MMMakoto Matsumoto
Makoto Matsumoto
SKShigeru Kawakami
Shigeru Kawakami
Liposomes are versatile carriers that can encapsulate various drugs; however, for delivery to the brain, they must be modified with a targeting ligand or other modifications to provide blood–brain barrier (BBB) permeability, while avoiding rapid clearance by reticuloendothelial systems through polyethylene glycol (PEG) modification. BBB-penetrating peptides act as brain-targeting ligands. In this study, to achieve efficient brain delivery of liposomes, we screened the functionality of eight BBB-penetrating peptides reported previously, based on high-throughput quantitative evaluation methods with in vitro BBB permeability evaluation system using Transwell, in situ brain perfusion system, and others. For apolipoprotein E mimetic tandem dimer peptide (ApoEdp), which showed the best brain-targeting and BBB permeability in the comparative evaluation of eight peptides, its lipid conjugate with serine–glycine (SG)5 spacer (ApoEdp-SG-lipid) was newly synthesized and ApoEdp-modified PEGylated liposomes were prepared. ApoEdp-modified PEGylated liposomes were effectively associated with human brain capillary endothelial cells via the ApoEdp sequence and permeated the membrane in an in vitro BBB model. Moreover, ApoEdp-modified PEGylated liposomes accumulated in the brain 3.9-fold higher than PEGylated liposomes in mice. In addition, the ability of ApoEdp-modified PEGylated liposomes to localize beyond the BBB into the brain parenchyma in mice was demonstrated via three-dimensional imaging with tissue clearing. These results suggest that ApoEdp-SG-lipid modification is an effective approach for endowing PEGylated liposomes with the brain-targeting ability and BBB permeability.

1 July 2020 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Closed access
PDF file
KOKoki Ogawa
Koki Ogawa
NKNaoya Kato
Naoya Kato
SKShigeru Kawakami
Shigeru Kawakami
Because the brain is the most important human organ, many brain disorders can cause severe symptoms. For example, glioma, one type of brain tumor, is progressive and lethal, while neurodegenerative diseases cause severe disability. Nevertheless, medical treatment for brain diseases remains unsatisfactory, and therefore innovative therapies are desired. However, the development of therapies to treat some cerebral diseases is difficult because the blood–brain barrier (BBB) or blood–brain tumor barrier prevents drugs from entering the brain. Hence, drug delivery system (DDS) strategies are required to deliver therapeutic agents to the brain. Recently, brain-targeted DDS have been developed, which increases the quality of therapy for cerebral disorders. This review gives an overview of recent brain-targeting DDS strategies. First, it describes strategies to cross the BBB. This includes BBB-crossing ligand modification or temporal BBB permeabilization. Strategies to avoid the BBB using local administration are also summarized. Intrabrain drug distribution is a crucial factor that directly determines the therapeutic effect, and thus it is important to evaluate drug distribution using optimal methods. We introduce some methods for evaluating drug distribution in the brain. Finally, applications of brain-targeted DDS for the treatment of brain tumors, Alzheimer’s disease, Parkinson’s disease, and stroke are explained.

4 September 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
TSTadaharu Suga
Tadaharu Suga
NKNaoya Kato
Naoya Kato
MHMASAYORI HAGIMORI
MASAYORI HAGIMORI
YFYuki Fuchigami
Yuki Fuchigami
NKNaotaka Kuroda
Naotaka Kuroda
SKShigeru Kawakami
Shigeru Kawakami

25 March 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
LGLongjian Geng
Longjian Geng
NKNaoya Kato
Naoya Kato
YKYukinobu Kodama
Yukinobu Kodama
HMHidefumi Mukai
Hidefumi Mukai
SKShigeru Kawakami
Shigeru Kawakami
Intratracheal (i.t.) administration, which takes advantage of the specific structure of the respiratory system, can effectively deliver nanoparticles to the lung. Much remains unknown about the i.t. administration of messenger RNA (mRNA)-lipid nanoparticles (LNPs) and the effect of lipid composition. In this study, we administered minute amounts of mRNA-LNP solutions into mice intratracheally and investigated the effect of lipid composition on protein expression in the lungs. We first validated higher protein expression with mRNA-LNP compared to that with mRNA-PEI complex and naked mRNA. Then, we evaluated the influence of lipid composition of LNPs on the protein expression and found that: 1) decreasing the PEG molarity from 1.5% to 0.5% could significantly increase the protein expression; 2) replacing DMG-PEG with DSG-PEG could slightly increase the protein expression; 3) using DOPE instead of DSPC could increase protein expression by an order of magnitude. We successfully prepared an mRNA-LNP with optimal lipid compositions that led to robust protein expression following i.t. administration, thus providing meaningful insights into advanced development of mRNA-LNPs for therapeutic i.t. administration.

1 October 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MHMASAYORI HAGIMORI
MASAYORI HAGIMORI
YCYorinao Chinda
Yorinao Chinda
TSTadaharu Suga
Tadaharu Suga
KYKazuto Yamanami
Kazuto Yamanami
NKNaoya Kato
Naoya Kato
SKShigeru Kawakami
Shigeru Kawakami
The mannose receptor, which is responsible for tumor invasion, proliferation, and metastasis in the tumor microenvironment, is overexpressed in tumor-associated macrophages. Mannose is commonly applied to PEGylated liposomes in macrophage-targeted cancer therapy. To develop a high functionality and quality (HFQ) lipid for macrophage-targeted liposomes, we designed a novel mannosylated lipid with improved mannose receptor binding affinity using serine-glycine repeats (SG)n. We synthesized Man(S)-(SG)5-SSK-K(Pal)2 using only a fluorenylmethyloxycarbonyl (Fmoc) protecting group solid-phase peptide synthesis method, which produced a high-quality lipid at a moderately good yield. We then prepared Man-(SG)5/PEGylated liposomes using a post-insertion technique to insert Man(S)-(SG)5-SSK-K(Pal)2 into the PEGylated liposomes. In vitro cell investigations revealed that the Man-(SG)5/PEGylated liposomes effectively associated with mouse peritoneal macrophages by interacting with the mannose receptors. The results suggest that we produced a novel high-quality, highly functional mannosylated lipid that is suitable for clinical drug delivery applications.